ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2026
Complement activation in kidney transplantation.
Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Glycan-encoded immune checkpoints and allorecognition: a mechanistic framework for transplantation and organ engineering.Frontiers in transplantation · 2026Review
- Metabolic dysregulation and antibody-mediated rejection after kidney transplantation: interacting mechanisms and emerging clinical strategies.Frontiers in immunology · 2026Review
- Multiple omics-based machine learning reveals peripheral blood immune cell landscape during acute rejection of kidney transplantation and constructs a precise non-invasive diagnostic strategy.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term graft survival remains a challenge in kidney transplantation and, due to scarcity of available organs, solutions such as xenotransplantation have been revived, and testing of new agents, including complement-targeting biologicals with potential to improve transplant outcomes, has been enhanced. The complement system plays a critical role in the reaction of the host's immune system to the transplanted foreign kidney. Activation of the complement system is strongly involved in ischemia/reperfusion-mediated injury and rejection of allografts as well as xenografts, and post-transplant recurrence rates are high in kidney diseases linked to complement system dysregulation. Therefore, the precise understanding of the complement activation cascade is important for the development of successful strategies that target complement before and after transplantation. This article compiles the current knowledge on the role of the complement system in kidney transplantation, examines recent developments in the clinical use of complement-targeting therapeutics and discusses the limitations of these approaches. While the current study results indicate that complement-targeting strategies are still in their early stages, promising findings related to the discovery of new agents encourage the redesign of existing therapeutic approaches and the development of more effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.